{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Patients with Previously Treated Metastatic Colorectal Cancer","Cancer"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Patients With Previously Treated Metastatic Colorectal Cancer","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2029912"],"location":["Czechia","United Kingdom","Portugal","Spain","Netherlands","Austria","Sweden","Belgium","Ireland","Finland","Italy","Slovakia","Lithuania","Germany"],"study_start_month":["6"],"keyword":["Amgen","Clinical Trial","Panitumumab","Oncology","EGFr"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","description":"The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.","dates":{"creation":"2006-06-15"},"accession":"2029912","cross_references":{"ClinicalTrials___gov":["NCT00339183"],"EU Clinical Trials Register":["2005-004676-20"]}}